Wen-Shuo Wu

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

Ohsang Kwon, Maryanne M. Senna, Rodney Sinclair et al. · American Journal of Clinical Dermatology · 2023 · 147 citations · Full text

Medicine, Dermatology, Pharmacology +13

Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)

Antonio Torrelo, Barbara Rewerska, María Laura Galimberti et al. · British Journal of Dermatology · 2023 · 86 citations · Full text

Medicine, Dermatology, Pharmacology +15

Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs

Yung‐Hung Luo, Chieh‐Hung Wu, Wen-Shuo Wu et al. · Journal of Thoracic Oncology · 2011 · 64 citations · Full text

Medicine, Genetics, Oncology +7

When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials

Brett King, Jerry Shapiro, Manabu Ohyama et al. · British Journal of Dermatology · 2023 · 54 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials

Brett King, Arash Mostaghimi, Yutaka Shimomura et al. · British Journal of Dermatology · 2022 · 53 citations · Full text

Medicine, Dermatology, Pharmacology +13